1.40

0.71% -0.01

After Hours: 1.45 0.05 +3.57%

Dogwood Therapeutics Inc (DWTX)

Overview News Price History Financials Discussions Forecast

Dogwood Therapeutics Inc stock is traded at $1.40, with a volume of 65,888. It is down -0.71% in the last 24 hours and down -27.84% over the past month. Dogwood Therapeutics Inc is a development-stage biopharmaceutical company focused on developing new medicines to treat pain and neuropathy. The pipeline is focused on treating chronic neuropathic pain and neuropathy. The Company operates in one segment and is a pre-revenue, development-stage biopharmaceutical company focused on developing new medicines to treat pain and peripheral neuropathy associated with cancer.

Previous Close:

$1.41

Open:

$1.45

24h Volume:

65,888

Relative Volume:

0.94

Market Cap:

$47.59M

Revenue:

Net Income/Loss:

$-28.32M

P/E Ratio:

-0.132

EPS:

-10.6039

Net Cash Flow:

$-15.52M

1W Performance:

-4.11%

1M Performance:

-27.84%

6M Performance:

-29.29%

1Y Performance:

-75.00%

1-Day Range:

$1.40

$1.54

1-Week Range:

$1.40

$1.72

52-Week Range:

$1.28

$7.0436

Dogwood Therapeutics Inc Stock (DWTX) Company Profile

Name

Dogwood Therapeutics Inc

Sector

Healthcare (1050)

Industry

Biotechnology (591)

Phone

(866) 620-8655

Address

44 MILTON AVENUE, ALPHARETTA

Employee

Twitter

Next Earnings Date

2026-11-05

Latest SEC Filings

DWTX's Discussions on Twitter

Compare DWTX vs VRTX, MRNA, REGN, ARGX, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
DWTX Dogwood Therapeutics Inc	1.40	47.59M	0	-28.32M	-15.52M	-10.60
VRTX Vertex Pharmaceuticals Inc	510.08	129.29B	12.34B	4.34B	3.71B	16.87
MRNA Moderna Inc	225.00	89.83B	2.23B	-3.19B	-1.60B	-8.1462
REGN Regeneron Pharmaceuticals Inc	746.54	76.86B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	825.03	51.88B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	189.76	40.67B	742.00K	-1.37B	-1.07B	-7.0731

Dogwood Therapeutics Inc Stock (DWTX) Latest News

Sep 02, 2026

H.C. Wainwright reiterates Dogwood Therapeutics stock rating at buy - Investing.com

Sep 02, 2026

H.C. Wainwright reiterates Dogwood Therapeutics stock rating at buy By Investing.com - Investing.com Australia

Sep 02, 2026

H.C. Wainwright reiterates Dogwood Therapeutics stock rating at buy By Investing.com - Investing.com Nigeria

Sep 02, 2026

H.C. Wainwright reiterates Dogwood Therapeutics stock rating at buy By Investing.com - Investing.com India

Sep 02, 2026

H.C. Wainwright reiterates Dogwood Therapeutics stock rating at buy By Investing.com - Investing.com Canada

Sep 02, 2026

H.C. Wainwright reiterates Dogwood Therapeutics stock rating at buy By Investing.com - Investing.com UK

Sep 02, 2026

Dogwood Therapeutics advances Halneuron for che... - Pluang

Sep 02, 2026

Sep 01, 2026

Dogwood Therapeutics Nears Phase 2b Readout for Halneuron Neuropathic Pain Treatment - TradingView

Sep 01, 2026

12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga

Sep 01, 2026

Dogwood Therapeutics Nears Phase 2b Readout for Halneuron Neuropathic Pain Treatment - Yahoo Finance

Sep 01, 2026

Aug 23, 2026

Dogwood (DWTX) Earnings Reading: The Available Earnings Metric Delivers a Beat in the Current Update; After Earnings: Shares Finish 6.87% Up in the Latest ReadingHigh Estimate Range - vinanet.vn

Aug 23, 2026

Aug 21, 2026

Dogwood (DWTX) Update: Records a 6.87% Increase to $2.49 at the Close; Boundary Watch: the Supplied Trading Band Runs From $2.37 to $2.61 in the Latest SessionImpulse Wave - vinanet.vn

Aug 21, 2026

Aug 20, 2026

Armistice Capital Expands Dogwood Therapeutics Stake Amid Biotec - GuruFocus

Aug 20, 2026

Dogwood (DWTX) Quarterly Results: EPS Lands Above Forecast; Market Move: Shares Move 7.79% Lower on the DayTax Rate Impact - vinanet.vn

Aug 20, 2026

Aug 19, 2026

Dogwood (DWTX) Earnings Reading: Profit Per Share Clears Its Benchmark in the Current Update; Latest Reaction - vinanet.vn

Aug 19, 2026

Aug 18, 2026

Research Analysts Offer Predictions for DWTX Q3 Earnings - MarketBeat

Aug 18, 2026

Aug 17, 2026

Dogwood to Host Virtual KOL Event to Discuss Halneuron® for the Treatment of Chemotherapy Induced Neuropathic Pain on September 1, 2026 - The Manila Times

Aug 17, 2026

Halneuron Has Been Tested on More Than 800 Patients—What’s Next? - Stock Titan

Aug 17, 2026

Dogwood to Host Virtual KOL Event to Discuss Halneuron® for the Treatment of Chemotherapy Induced Neuropathic Pain on September 1, 2026 - markets.businessinsider.com

Aug 17, 2026

What is HC Wainwright's Forecast for DWTX FY2029 Earnings? - MarketBeat

Aug 17, 2026

Aug 15, 2026

Dogwood Therapeutics, Inc. (NASDAQ: DWTX) Stock Price, News & Analysis - kalkine.ca

Aug 15, 2026

Dogwood Therapeutics, Inc. (NASDAQ: DWTX) Stock Price, News & Analysis - kalkine.com.au

Aug 15, 2026

Aug 14, 2026

Dogwood Therapeutics, Inc. 2026: Revenue ($14.06M), EPS ($0.34) — 10-Q Summary - TradingView

Aug 14, 2026

Dogwood Therapeutics (DWTX) logs $16.5M H1 loss and warns on going concern outlook - Stock Titan

Aug 14, 2026

Armistice Capital (DWTX) discloses 9.99% Dogwood Therapeutics ownership in 13G/A - Stock Titan

Aug 14, 2026

Maxim Group Maintains Dogwood Therapeutics(DWTX.US) With Buy Rating, Maintains Target Price $15 - Moomoo

Aug 14, 2026